Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Registry Study of a Primary Melanoma Gene-signature to Predict Sentinel Node (SN) Status and Determine Its Prognostic Value for More Accurate Staging of SN-negative Melanoma Patients.

NCT04759781 is registered in ClinicalTrials.gov with SkylineDx as lead sponsor.

NCT NCT04759781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04759781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Registry Study of a Primary Melanoma Gene-signature to Predict Sentinel Node (SN) Status and Determine Its Prognostic Value for More Accurate Staging of SN-negative Melanoma Patients.
Lead sponsor
SkylineDx
Phase
Observational
Overall status
Active, not recruiting
Start date
August 25, 2021
Completion date
June 30, 2029
Enrollment
1,820 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma